Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study

[1]  Claus Svarer,et al.  Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients , 2008, Neuropsychopharmacology.

[2]  R. Miller,et al.  An Australian Brain Bank: a critical investment with a high return! , 2008, Cell and Tissue Banking.

[3]  Xu-Feng Huang,et al.  No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia , 2007, Neuroscience bulletin.

[4]  W. Maier,et al.  5-HT2A receptor density is decreased in the at-risk mental state , 2007, Psychopharmacology.

[5]  J. Bobes,et al.  Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[6]  Xu-Feng Huang,et al.  Fatty acids differentially affect serotonin receptor and transporter binding in the rat brain , 2006, Neuroscience.

[7]  K. Zavitsanou,et al.  Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain , 2006, Behavioural Brain Research.

[8]  Lin He,et al.  Association study of serotonin 2A receptor (5-HT2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis. , 2006, Biochemical and biophysical research communications.

[9]  Michael Wagner,et al.  Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia , 2005, Anatomy and Embryology.

[10]  Xu-Feng Huang,et al.  Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia , 2005, Journal of neuroscience research.

[11]  M. Reuter,et al.  Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5‐HT2a and COMT polymorphisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[12]  Brian Dean,et al.  5-HT2A and muscarinic receptors in schizophrenia: a postmortem study , 2005, Neuroscience Letters.

[13]  B. Dean,et al.  Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects , 2004, Schizophrenia Research.

[14]  M. Crismon,et al.  Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. , 2004, Clinical therapeutics.

[15]  S. Faraone,et al.  Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia , 2004, Schizophrenia Research.

[16]  S. Watson,et al.  Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia , 2004, Biological Psychiatry.

[17]  A. Mortimer,et al.  ARE THE COGNITIVE EFFECTS OF ATYPICAL ANTIPSYCHOTICS INFLUENCED BY THEIR AFFINITY TO 5HT-2A RECEPTORS? , 2004, The International journal of neuroscience.

[18]  Georg Juckel,et al.  Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity , 2003, Schizophrenia Research.

[19]  J. Leysen,et al.  5-HT2A and 5-HT2C receptors and their atypical regulation properties. , 2003, Life sciences.

[20]  Vincent Magnotta,et al.  Morphology of the lateral superior temporal gyrus in neuroleptic naı̈ve patients with schizophrenia: relationship to symptoms , 2003, Schizophrenia Research.

[21]  Paul J. Harrison,et al.  RNA editing of the 5-HT2C receptor is reduced in schizophrenia , 2001, Molecular Psychiatry.

[22]  Shitij Kapur,et al.  A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia , 2000, Psychiatry Research: Neuroimaging.

[23]  B. Dean,et al.  Serotonin2A receptors are reduced in the planum temporale from subjects with schizophrenia , 2000, Schizophrenia Research.

[24]  P. Luiten,et al.  Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory , 1999, Progress in Neurobiology.

[25]  Marie-Laure Paillère-Martinot,et al.  No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET , 1998, Schizophrenia Research.

[26]  E. Smeraldi,et al.  No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population. , 1997, American journal of medical genetics.

[27]  Paul J. Harrison,et al.  5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.

[28]  B. Dean,et al.  Decreased frontal cortical serotonin2A receptors in schizophrenia , 1996, Schizophrenia Research.

[29]  Richard S. J. Frackowiak,et al.  A functional neuroanatomy of hallucinations in schizophrenia , 1995, Nature.

[30]  J. Cassel,et al.  Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications , 1995, Neuroscience.

[31]  J. Kehne,et al.  The role of 5-HT2A receptors in antipsychotic activity. , 1995, Life sciences.

[32]  K. Kuriyama,et al.  Muscarinic M1 receptor mediated inhibition of GABA release from rat cerebral cortex , 1994, Neurochemistry International.

[33]  D. Morilak,et al.  Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain , 1993, Neuroscience.

[34]  Chao Deng 邓超,et al.  No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia , 2007, Neuroscience Bulletin.

[35]  Xu-Feng Huang,et al.  Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia , 2005, Experimental Brain Research.

[36]  C. Büchel,et al.  Neuroanatomy of "hearing voices": a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. , 2004, Cerebral cortex.

[37]  Brian Dean.  Proceedings of the Australian Neuroscience Society Symposium: Schizophrenia A PREDICTED CORTICAL SEROTONERGIC/CHOLINERGIC/GABAERGIC INTERFACE AS A SITE OF PATHOLOGY IN SCHIZOPHRENIA , 2001, Clinical and experimental pharmacology & physiology.